Evidence map›Paper›PMID 29665866›Full record

ArticleBreast cancer research : BCR2018

Mitochondrial DNA copy number variation, leukocyte telomere length, and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study.

Daniele Campa, Myrto Barrdahl, Aurelia Santoro, Gianluca Severi, Laura Baglietto, Hanane Omichessan, Rosario Tumino, H B As Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass and 11 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. The Evaluation of Mass/DNA Copy Number of Mitochondria in Umbilical Cord Blood-derived Hematopoietic Stem Cells Cocultured with MSCs.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Myrto BarrdahlDivision of Cancer Epidemiology, German Cancer Research Center/Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
Aurelia SantoroDepartment of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Gianluca SeveriCentre de Recherche en épidémiologie et Santé des populations (CESP), Faculté de médecine - Université Paris-Sud, Faculté de médecine - Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut national de la santé et de la recherche médicale (INSERM), Université Paris-Saclay, 94805, Villejuif, France.
Laura BagliettoCentre de Recherche en épidémiologie et Santé des populations (CESP), Faculté de médecine - Université Paris-Sud, Faculté de médecine - Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut national de la santé et de la recherche médicale (INSERM), Université Paris-Saclay, 94805, Villejuif, France.
Hanane OmichessanCentre de Recherche en épidémiologie et Santé des populations (CESP), Faculté de médecine - Université Paris-Sud, Faculté de médecine - Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut national de la santé et de la recherche médicale (INSERM), Université Paris-Saclay, 94805, Villejuif, France.
Rosario TuminoCancer Registry and Histopathology Department, "Civic - M.P. Arezzo" Hospital, Azienda Sanitaria Provinciale Di Ragusa, Ragusa, Italy.
H B As Bueno-de-MesquitaDepartment for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, The Netherlands.
Petra H PeetersDepartment of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Elisabete WeiderpassDepartment of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Maria-Dolores ChirlaqueDepartment of Epidemiology, Regional Health Council, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain.
Miguel Rodríguez-BarrancoConsorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Antonio AgudoUnit of Nutrition and Cancer, Bellvitge Biomedical Research Institute (IDIBELL), Catalan Institute of Oncology, L'Hospitalet de Llobregat, 08908, Barcelona, Spain.
Marc GunterInternational Agency for Research on Cancer, Lyon, France.
Laure DossusInternational Agency for Research on Cancer, Lyon, France.
Vittorio KroghEpidemiology and Prevention Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Nazionale dei Tumori, Via Venezian, 120133, Milan, Italy.
Giuseppe MatulloDepartment Medical Sciences, University of Torino and Human Genetics Foundation (HuGeF), Torino, Italy.
Antonia TrichopoulouHellenic Health Foundation, 11527, Athens, Greece.
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health University of Oxford, Oxford, OX3 0NR, UK.
Federico CanzianGenomic Epidemiology Group, German Cancer Research Center/Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center/Deutsches Krebsforschungszentrum (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. r.kaaks@dkfz.de.

Funding

Cancer Research UK 14136Cancer Research UK 16491Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1World Health Organization 001
6 · The paper itself

Abstract

backgroundLeukocyte telomere length (LTL) and mitochondrial genome (mtDNA) copy number and deletions have been proposed as risk markers for various cancer types, including breast cancer (BC).

methodsTo gain a more comprehensive picture on how these markers can modulate BC risk, alone or in conjunction, we performed simultaneous measurements of LTL and mtDNA copy number in up to 570 BC cases and 538 controls from the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. As a first step, we measured LTL and mtDNA copy number in 96 individuals for which a blood sample had been collected twice with an interval of 15 years.

resultsAccording to the intraclass correlation (ICC), we found very good stability over the time period for both measurements, with ICCs of 0.63 for LTL and 0.60 for mtDNA copy number. In the analysis of the entire study sample, we observed that longer LTL was strongly associated with increased risk of BC (OR 2.71, 95% CI 1.58-4.65, p = 3.07 × 10

conclusionsWe observed a very good correlation between the markers over a period of 15 years. We confirm a role of LTL in BC carcinogenesis and suggest an effect of mtDNA copy number on BC risk.

Indexed as

AdultAgedBreast NeoplasmsCohort StudiesDNA Copy Number VariationsDNA, MitochondrialEuropeFemaleHumansLeukocytesMiddle AgedNutrition AssessmentProspective StudiesRisk FactorsTelomereTelomere HomeostasisDNA, MitochondrialBreast cancerCancer epidemiologyMitochondrial copy numberTelomere length

Identifiers

PMID29665866
PMCPMC5905156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.